Hyperglycemia management in the hospital setting

American Journal of Health-System Pharmacy

Volumn 64, Issue 10 SUPPL., 2007, Pages

  Hassan, Erkan ^a  

^a VISICU   (United States)

Author keywords

Antidiabetic agents; Computers; Decision making; Dosage schedules; Errors, medication; Hospitals; Hyperglycemia; Insulin; Insulin glargine; Insulins; Nutrition; Pharmacodynamics; Toxicity

Indexed keywords

ANTIDIABETIC AGENT; GLUCOCORTICOID; GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN;

BOLUS INJECTION; COMPUTER SYSTEM; CONFERENCE PAPER; CONTINUOUS INFUSION; DIETARY INTAKE; DISEASE SEVERITY; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; MEDICAL DECISION MAKING; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 34249030304     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070102     Document Type: Conference Paper

References (26)

1. Clement S, Braithwaite SS, Magee MF et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004; 27:553-91.
2. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care. 2006; 29(suppl 1):S4-42.
3. Garber AJ, Moghissi ES, Bransome ED Jr et al. American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract. 2004; 10:77-82. www.aace.com/pub/pdf/guidelines/ InpatientDiabetesPositionStatement.pdf (accessed 2006 Dec 20).
4. Bode BW, Braithwaite SS, Steed RD et al. Intravenous insulin infusion therapy: indications, methods, and transition to subcutaneous insulin therapy. Endocr Pract. 2004; 10(suppl 2):71-80.
5. Luna B, Feinglos MN. Drug-induced hyperglycemia. JAMA. 2001; 286:1945-8.
6. ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control: a call to action. Diabetes Care. 2006; 29:1955-62.
7. Inzucchi, SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med. 2006; 355;1903-11.
8. Van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patient. N Engl J Med. 2001; 345:1359-67.
9. Furnary AP, Gao G, Grunkemeier GL et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2003; 125:1007-21.
10. Goldberg PA, Siegel MD, Sherwin RS et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care. 2004; 27:461-7.
11. Garg AX, Adhikari NK, McDonald H et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes. JAMA. 2005; 293:1223-38.
12. Queale WS, Seidler AJ, Brancati FL. Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. Arch Intern Med. 1997; 157:545-52.
13. Browning LA, Dumo P. Sliding-scale insulin: an antiquated approach to glycemic control in hospitalized patients. Am J Health-Syst Pharm. 2004; 61:1611-4.
14. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am. 2001; 30:935-82.
15. McEvoy GK, ed. Insulins general statement. In: AHFS Drug Information 2006. Bethesda, MD: American Society of Health-System Pharmacists; 2006:3086-95.
16. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000; 49:2142-8.
17. Apidra package insert. Kansas City, MO: Aventis Pharmaceuticals Inc.; November 2005.
18. Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005; 28:1107-12.
19. Leahy JL. Intensive insulin therapy in type 1 diabetes mellitus. In: Leahy JL, Cefalu WW, eds. Insulin Therapy. New York, NY: Marcel Dekker Inc.; 2002:87-112.
20. Campbell RK, White JR, Levien T et al. Insulin glargine. Clin Ther. 2001; 23:1938-57.
21. McEvoy GK, ed. Insulin glargine. In: AHFS Drug Information 2006. Bethesda, MD: American Society of Health-System Pharmacists; 2006:3098-9.
22. Levemir package insert. Princeton, NJ: Novo Nordisk Inc.; October 2005.
23. Peterson GE. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin. 2006; 22:2613-9.
24. Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004; 53:1614-20.
25. Davidson PC, Steed RD, Bode BW. Glu-commander: a computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operation. Diabetes Care. 2005; 28:2418-23.
26. Levetan CS, Passaro M, Jablonski K et al. Unrecognized diabetes among hospitalized patients. Diabetes Care. 1998; 21:246-9.